Schizophrenia: Reversal of atypical antipsychotic drug-induced obesity and its related metabolic disorders

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1027493

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Atypical antipsychotic drugs such as olanzapine are commonly used to treat mental illnesses such as schizophrenia. While these drugs are effective, their side effects of obesity and metabolic disorders are a major hurdle leading to a serious lack of compliance in taking medication. This project aims to develop better antipsychotic treatment with reduced side-effects including obesity and metabolic disorders for mental illness patients.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $619,854.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Psychiatry (incl. Psychotherapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antipsychotic | energy balance | hypothalamus | obesity | schizophrenia

Related Links